| Today's Big NewsNov 11, 2022 |
|
Talent matters more than ever. And Greater Philadelphia’s growth and development of this critical asset is one reason JLL ranked the region as its No. 5 Life Sciences cluster in the U.S. Learn how the region can fuel your company’s growth. Learn more. 
|
|
| By Nick Paul Taylor Deep into the fall season, biotechs are freeing themselves of dead wood at a rapid pace. The latest batch of quarterly updates saw Atreca, aTyr Pharma, Histogen, Lisata Therapeutics, Poseida Therapeutics and Rain Therapeutics trim their pipelines. |
|
|
|
By Kevin Dunleavy How did investors receive news of Biogen’s hire of Christopher Viehbacher as the company’s CEO? The reaction is decidedly mixed, with lots of strong opinions on both sides, according to an anonymous survey conducted by Mizuho Securities. |
By Frank Diamond Nurses feel that Kaiser Permanente doesn’t do enough to ease the burdens brought on partly by COVID-19. So, they’re going on strike for three days. |
By Angus Liu The safety brouhaha around PARP inhibitors’ use in ovarian cancer is taking yet another turn. GSK has yielded to FDA pressure and is limiting Zejula's second-line maintenance use in ovarian cancer, putting the fate of other drugs in question. |
|
Wednesday, November 16, 2022 | 11am ET / 8am PT Process characterization is an important step in the product development journey. Join this webinar where experts share case studies in developing a stepwise approach for process validation. Register now. 
|
|
By Conor Hale The NFL aims to expand a study that tracks on-field head impacts using sensors embedded in custom mouthguards, by adding NCAA players from participating universities. |
By Dave Muoio Included among the payers, drugmakers, associations and other groups are private and federal health systems representing over 1,080 hospitals, HHS said in an announcement timed with COP27. |
By Fraiser Kansteiner The U.S. FDA approved Imjudo and Imfinzi for adults with metastatic non-small cell lung cancer, AstraZeneca said Friday. The green light comes right on the heels of Imjudo’s first approval in October—also in tandem with Imfinzi—in the most common type of liver cancer. |
By Andrea Park Johnson & Johnson and SciBase aim to reverse growing rates of eczema around the world, with new technology that could detect the condition in infants, before it has a chance to fully develop and while prevention is still an option. |
By James Waldron Irish biotech Nabriva Therapeutics has responded to the tough financial climate by putting all its chips on the approved bacterial skin medicine Sivextro, meaning that its R&D projects and 40% of staff are now surplus to requirements. |
By Andrea Park Tandem Diabetes Care’s automatic insulin-adjusting technology, which is currently FDA-cleared only for the Type 1 diabetes population, was recently put to the test in a study dedicated solely to Type 2 users—and emerged victorious. |
By Helen Floersh A next-generation oncolytic virus carrying a tumor-tackling protein armed with cytokines and cetuximab showed survival benefits in mouse models of glioblastoma multiforme, a type of brain cancer. |
By Heather Landi Aetna has tapped tech-enabled primary care group Crossover Health to provide access to medical services—both in-person and virtual doctor visits—to Seattle-area employers and their workers. |
By Max Bayer New charges from the SEC allege that an insider trading scheme related to Merck & Co.'s acquisition of Pandion was a family affair. The brother of one of the two men first charged in July was also tipped off about the deal, the agency has alleged. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we share some highlights from Fierce Biotech's Cell and Gene Therapy Forum in case you missed it. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
